2013, Number 2
<< Back Next >>
Revista del Hospital Psiquiátrico de La Habana 2013; 10 (2)
Malignant Syndrome Due to Neuroleptics, Case
Rodríguez ME, Rodríguez MM
Language: Spanish
References: 12
Page:
PDF size: 33.71 Kb.
ABSTRACT
The malignant syndrome due to neuroleptics is a critical condition of thermoregulation caused by
the use of neuroleptics, both the ones from the first generation as well as the modern ones; its
mortality is high, but with the new studies this condition has diminished significantly.
Different drugs are used for its treatment, among them there are the ones used on Parkinson
disease. A 56 years old black feminine patient that was treated with conventional neuroleptics due
to an unbalance at a psychotic level of a hysterical disease; came to our service with hyperthermia,
rigidity, dehydration among other symptoms .The possibility of a malignant hyperthermia was
assessed and she was treated with anti-Parkinson and anti- calcium medicines in a intermeddle
care unit. She left the unit seven days later with a total recovery of the neurological state.
REFERENCES
Neuhut R, Lindenmayer JP, Silva R. Neuroleptic malignant syndrome in children and adolescents on atypical antipsychotic medication: a review. J Child Adolesc Psychopharmacol. 2009; 19 (4):415-22.
Trollor JN, Chen X, Sachdev PS. Neuroleptic malignant syndrome associated with atypical antipsychotic drugs. CNS Drugs 2009; 23 (6):477-92.
Vargas A, Gómez-Restrepo C. Síndrome neuroléptico maligno. Rev Colomb Psiquiatr 2007; 36(Suppl 1):101S-125S.
Strawn JR, Keck PE, Jr., Caroff SN. Neuroleptic malignant syndrome. Am J Psychiatry 2007 june; 164 (6):870-6.
Gortney JS, Fagan A, Kissack JC. Neuroleptic malignant syndrome secondary to quetiapine. Ann Pharmacother 2009; 43(4):785-91.
Stevens DL. Association between selective serotonin-reuptake inhibitors, secondgeneration antipsychotics, and neuroleptic malignant syndrome. Ann Pharmacother 2008; 42 (9):1290-7.
Reilly TH, Kirk MA. Atypical antipsychotics and newer antidepressants. Emerg Med Clin North Am 2007; 25(2):477-97.
Reulbach U, Dutsch C, Biermann T, Sperling W, Thuerauf N, Kornhuber J et al. Managing an effective treatment for neuroleptic malignant syndrome. Crit Care 2007 Jan; 11(1):R4.
Chan LG, Lee J, Ng BT, Chua HC, Sim K, Lee EL. Rare neuropsychiatric sequelae following neuroleptic malignant syndrome: a case report and review of the literature. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32(8):1998-9.
Labuda A, Cullen N. Brain injury following neuroleptic malignant syndrome: case report and review of the literature. Brain Inj 2006; 20(7):775-8.
Seitz D. Hypophosphathemia and Neuroleptic Malignant Syndrome. J Clin Psychopharmacol 2007 June; 27(3):302-3.
Síndrome neuroléptica maligna. Rev Bras Clin Med. São Paulo. 2012 set-out; 10(5):440- 5. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 3rd ed. Washington,DC. American Psychiatric Press, 1980.